✉news WorldUS Politics first seen 6 h ago, last 3 h ago, peak #27
Five-Year Data on Duchenne Drug Brogidirsen Presented at Muscle Congress
Original: Brogidirsen (NS-089/NCNP-02) 5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 World Muscle Society Congress
Five-year clinical trial data for brogidirsen (NS-089/NCNP-02), an investigational treatment for Duchenne muscular dystrophy, has been presented at the 2026 World Muscle Society Congress. The long-term results are being shared with specialists in neuromuscular medicine, offering the fullest picture yet of the drug's safety and effectiveness over five years in patients with the muscle-wasting disease.
Why now: Long-term trial results for a potential Duchenne muscular dystrophy therapy are of keen interest to patients, families and clinicians awaiting new treatment options.
BrogidirsenDuchenne muscular dystrophyWorld Muscle Society
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/604034